Overview

Raised to Date: Raised: $1,034,009

Deal Terms

Investment Momentum

Company Profile

Deal Summary

Financials

Funding History

Growth Charts

Total Commitments ($USD)

Platform

Wefunder

Start Date

06/01/2023

Close Date

04/29/2024

Min. Goal

$150,000

Max. Goal

$3,000,000

Min. Investment

$250

Security Type

Convertible Note

Series

Series A

SEC Filing Type

RegCF    

Early Bird Val. Cap

$70,000,000

Valuation Cap

$80,000,000

Discount

20%

Venture Capital Investors:

KVK Tech

Rolling Commitments ($USD)

Status

Active

Reporting Date

04/18/2024

Days Remaining

10

% of Min. Goal

689%

% of Max. Goal

34%

Likelihood of Max

Avg. Daily Raise

$3,211

# of Investors

314

Momentum

Create a free account today to gain access to KingsCrowd analytics.

Logos provided by Clearbit

Sen-Jam Pharmaceutical

Year Founded

2017

Industry

Healthcare & Pharmaceuticals

Tech Sector

Biotech

Distribution Model

B2C

Margin

Medium

Capital Intensity

Low

Location

Huntington, New York

Business Type

Growth

Company Website

Sen-Jam Pharmaceutical, with a valuation of $80 million, is raising funds on Wefunder. The pharmaceutical company makes highly accessible, safe, and affordable drugs that work. The drugs of Sen-Jam Pharmaceutical combine NSAIDs and antihistamines to prevent inflammation and associated pain. Sen-Jam Pharmaceutical is majorly targeting opioid withdrawal, alcohol hangover prevention, and COVID-19 therapeutic. The company has a strong global IP portfolio with 40 patents and world-class partners. Jim Iversen and Jackie Iversen founded Sen-Jam Pharmaceutical in August 2017. The current crowdfunding campaign has a minimum target of $150,000 and a maximum target of $3 million. The campaign proceeds will be used for product development, regulatory affairs, marketing, communications, intellectual property advancement, and operating expenses.

Summary Profit and Loss Statement

	FY 2022	FY 2021
Revenue	$0	$0
COGS	$0	$0
Tax	$0	$0
Net Income	$-3,983,709	$-417,348

Summary Balance Sheet

	FY 2022	FY 2021
Cash	$181,148	$64,694
Accounts Receivable	$0	$0
Total Assets	$663,018	$560,194
Short-Term Debt	$1,992,097	$47,033
Long-Term Debt	$170,896	$857,159
Total Liabilities	$2,162,993	$904,192

Financials as of: 06/01/2023

Create a free account today to gain access to KingsCrowd analytics.

Raise History

Offering Name	Close Date	Platform	Valuation/Cap	Total Raised	Security Type	Status	Reg Type
Sen-Jam Pharmaceutical	04/28/2024	Wefunder	$80,000,000	$1,034,009	Convertible Note	Active	RegCF
Sen-Jam Pharmaceutical	01/05/2024	Self Managed	-	-	Convertible Note	Funded	RegD 506(c)
Sen-Jam Pharmaceutical	01/10/2023	StartEngine	$69,979,019	$312,093	Equity - Common	Funded	RegCF
Sen-Jam Pharmaceutical	07/30/2022	Wefunder	$25,000,000	$1,008,951	Convertible Note	Funded	RegCF

Create a free account today to gain access to KingsCrowd analytics.

• Price per Share
• Valuation
• Revenue
• Employees

Price per Share Valuation Revenue Employees

Price per Share History

Note: Share prices shown in earlier rounds may not be indicative of any stock splits.

Valuation History

Revenue History

Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.

Employee History

Sen-Jam: Pioneering Anti-Inflammatory Solutions

In a relentless pursuit to revolutionize the treatment of inflammation, Sen-Jam Pharmaceutical is emerging as a formidable player in the biotech industry. Co-founder and Chief Clinical Officer Jacqueline Iversen brings a unique perspective, blending her extensive pharmaceutical knowledge with a patient-first approach. Sen-Jam stands out in the $217 billion market with its groundbreaking solutions for acute and chronic inflammation, impacting areas as diverse as hangovers, opioid withdrawal, and upper respiratory infections. We caught up with Iverson to learn about her deep-rooted passion for holistic pharmacy and vision for addressing systemic inflammation.

Read Founder Interview